TY - JOUR
T1 - A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults
T2 - The DEFINE Study
AU - Lat, Ishaq
AU - Daley, Mitchell J.
AU - Shewale, Anand
AU - Pangrazzi, Mark H.
AU - Hammond, Drayton
AU - Olsen, Keith M.
AU - Teevan, Colleen
AU - Erdman, Michael
AU - Milicevic, Lori
AU - Hyche, Stephanie
AU - Woolridge, John
AU - Patel, Gourang
AU - DeMott, Joshua
AU - Dalton, Kaitlyn
AU - Sokol, Sarah
AU - Bullard, Heather
AU - Miller, Mary K.
AU - Pierce, Tamra
AU - Flannery, Alexander H.
AU - Bissell, Brittany D.
AU - Thompson Bastin, Melissa L.
AU - Jennings, Katherine
AU - Barra, Megan E.
AU - Degrado, Jeremy R.
AU - Gilmore, James F.
AU - Kovacevic, Mary P.
AU - Schurr, James W.
AU - Szumita, Paul
AU - Hsin, Lin
AU - Lopez, Natasha
AU - Evans, Danielle
AU - Holzhausen, Jenna
AU - Ice, Calvin
AU - Yost, Raymond
AU - Zimmer, Jerrod D.
AU - Smith, Michael P.
AU - Zimmerman, Lisa H.
AU - Kenes, Michael P.
AU - Kaplan, Justin
AU - Delibert, Samantha
AU - Torbich, Heather
AU - Chen, Alyssa
AU - Bass, Stephanie
AU - Gowan, Mollie
AU - Palm, Nicole
AU - Sacha, Gretchen
AU - Bauer, Seth
AU - Welch, Sarah
AU - Reale, Matthew
AU - Finoli, Lauren
N1 - Publisher Copyright:
© 2018 Pharmacotherapy Publications, Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Objective: This study was conducted to describe the prevalence, epidemiology, and clinical outcomes of multidrug-resistant (MDR) organism (MDRO) pneumonia in critically ill patients. Methods: A multicenter, prospective, observational study of patients admitted to 60 intensive care units (ICUs), from 34 hospitals, in the United States from November to December 2016. Adults (> 18 yrs) receiving antimicrobial therapy at least 5 days for pneumonia were included. Patients were classified into two categories, with or without MDRO, and subcategorized by pneumonia type. Measurements and main results: Demographics, medication histories, and health care exposure were collected during ICU admission and compared using t test and chi-square tests. Multivariate logistic regression was used to determine predictive factors for MDRO pneumonia and hospital mortality. Of 652 patients, 92 patients (14.1%) developed MDR pneumonia. Predictors of MDRO pneumonia were acid suppression therapy within the previous 90 days (odds ratio [OR] 1.88 [1.14–3.09]; p=0.013), mechanical ventilation (OR 1.96 [1.14–3.35]; p<0.001), and history of MDRO infection (OR 4.74 [2.21–10.18]; p<0.001). Appropriate initial antimicrobial selection occurred in 58 patients (63%) with MDRO pneumonia compared to 464 patients (82.7%) in patients without MDRO pneumonia (p<0.001). MDRO pneumonia was not associated with hospital mortality (18.5% vs 17.6%, p=0.087). Conclusions: In a broad cohort of critically ill patients, MDRO pneumonia is infrequent, and associated with factors describing the intensity of health care provided. Presence of MDRO pneumonia is not associated with hospital mortality. Further study is needed to clarify risk factors for multidrug-resistant pneumonia in critically ill patients.
AB - Objective: This study was conducted to describe the prevalence, epidemiology, and clinical outcomes of multidrug-resistant (MDR) organism (MDRO) pneumonia in critically ill patients. Methods: A multicenter, prospective, observational study of patients admitted to 60 intensive care units (ICUs), from 34 hospitals, in the United States from November to December 2016. Adults (> 18 yrs) receiving antimicrobial therapy at least 5 days for pneumonia were included. Patients were classified into two categories, with or without MDRO, and subcategorized by pneumonia type. Measurements and main results: Demographics, medication histories, and health care exposure were collected during ICU admission and compared using t test and chi-square tests. Multivariate logistic regression was used to determine predictive factors for MDRO pneumonia and hospital mortality. Of 652 patients, 92 patients (14.1%) developed MDR pneumonia. Predictors of MDRO pneumonia were acid suppression therapy within the previous 90 days (odds ratio [OR] 1.88 [1.14–3.09]; p=0.013), mechanical ventilation (OR 1.96 [1.14–3.35]; p<0.001), and history of MDRO infection (OR 4.74 [2.21–10.18]; p<0.001). Appropriate initial antimicrobial selection occurred in 58 patients (63%) with MDRO pneumonia compared to 464 patients (82.7%) in patients without MDRO pneumonia (p<0.001). MDRO pneumonia was not associated with hospital mortality (18.5% vs 17.6%, p=0.087). Conclusions: In a broad cohort of critically ill patients, MDRO pneumonia is infrequent, and associated with factors describing the intensity of health care provided. Presence of MDRO pneumonia is not associated with hospital mortality. Further study is needed to clarify risk factors for multidrug-resistant pneumonia in critically ill patients.
KW - bacterial resistance
KW - critical care
KW - infectious disease
UR - http://www.scopus.com/inward/record.url?scp=85054312441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054312441&partnerID=8YFLogxK
U2 - 10.1002/phar.2171
DO - 10.1002/phar.2171
M3 - Article
C2 - 30101412
AN - SCOPUS:85054312441
SN - 0277-0008
VL - 39
SP - 253
EP - 260
JO - Pharmacotherapy
JF - Pharmacotherapy
IS - 3
ER -